ATE356804T1 - Inhibitoren von mitotischem kinesin - Google Patents
Inhibitoren von mitotischem kinesinInfo
- Publication number
- ATE356804T1 ATE356804T1 AT03741969T AT03741969T ATE356804T1 AT E356804 T1 ATE356804 T1 AT E356804T1 AT 03741969 T AT03741969 T AT 03741969T AT 03741969 T AT03741969 T AT 03741969T AT E356804 T1 ATE356804 T1 AT E356804T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibitors
- mitotic kinesin
- compounds
- ksp kinesin
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38882802P | 2002-06-14 | 2002-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE356804T1 true ATE356804T1 (de) | 2007-04-15 |
Family
ID=29736550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03741969T ATE356804T1 (de) | 2002-06-14 | 2003-06-12 | Inhibitoren von mitotischem kinesin |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7301028B2 (de) |
| EP (1) | EP1515949B1 (de) |
| JP (1) | JP4463679B2 (de) |
| AT (1) | ATE356804T1 (de) |
| AU (1) | AU2003276005B2 (de) |
| CA (1) | CA2486215A1 (de) |
| DE (1) | DE60312516T2 (de) |
| ES (1) | ES2282647T3 (de) |
| WO (1) | WO2003106417A1 (de) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7230000B1 (en) | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
| US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US7009049B2 (en) | 2002-02-15 | 2006-03-07 | Cytokinetics, Inc. | Syntheses of quinazolinones |
| JP4664597B2 (ja) | 2002-04-17 | 2011-04-06 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
| US7166595B2 (en) | 2002-05-09 | 2007-01-23 | Cytokinetics, Inc. | Compounds, methods and compositions |
| AU2003270015A1 (en) | 2002-05-09 | 2003-12-02 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| WO2003103575A2 (en) | 2002-05-23 | 2003-12-18 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| IL165624A0 (en) | 2002-06-14 | 2006-01-15 | Merck & Co Inc | Mitotic kinesin inhibitors |
| CA2489367A1 (en) | 2002-06-14 | 2003-12-24 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| ATE423110T1 (de) | 2002-07-17 | 2009-03-15 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen |
| WO2004009036A2 (en) | 2002-07-23 | 2004-01-29 | Cytokinetics, Inc. | Compounds compositions and methods |
| WO2004034972A2 (en) | 2002-09-30 | 2004-04-29 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| US7235580B2 (en) * | 2002-10-18 | 2007-06-26 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| US7465746B2 (en) * | 2003-08-15 | 2008-12-16 | Merck & Co., Inc. | Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP |
| AR045342A1 (es) * | 2003-08-15 | 2005-10-26 | Merck & Co Inc | Inhibidores de quinesina mitotica |
| US7638549B2 (en) | 2003-08-15 | 2009-12-29 | Merck & Co. Inc. | Mitotic kinesin inhibitors |
| CA2533889A1 (en) | 2003-08-15 | 2005-03-03 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| EP1692112A4 (de) | 2003-12-08 | 2008-09-24 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren |
| US7572914B2 (en) | 2003-12-19 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| DE602005008953D1 (de) | 2004-05-21 | 2008-09-25 | Novartis Vaccines & Diagnostic | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin |
| MXPA06014909A (es) | 2004-06-18 | 2007-02-28 | Chiron Corp | Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer. |
| CA2571824A1 (en) * | 2004-07-01 | 2006-01-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| WO2006023931A2 (en) | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| EP1812439B2 (de) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinaseinhibitoren |
| EP1807399A2 (de) | 2004-10-19 | 2007-07-18 | Novartis Vaccines and Diagnostics, Inc. | Indol- und benzimidazolderivate |
| CN1319978C (zh) * | 2005-04-06 | 2007-06-06 | 西南合成制药股份有限公司 | 康布瑞汀化合物的制备方法 |
| ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
| PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP1982718A4 (de) * | 2006-02-09 | 2010-05-12 | Daiichi Sankyo Co Ltd | Pharmazeutische zusammensetzung zur krebsbekämpfung |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| KR101464385B1 (ko) | 2006-04-19 | 2014-11-21 | 노파르티스 아게 | ６-ｏ-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 ｃｓｆ-１ｒ 신호전달의 억제 방법 |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
| MX2009005071A (es) | 2006-11-13 | 2009-05-25 | Novartis Ag | Compuestos de pirazol y triazol sustituidos como inhibidores de ksp. |
| GEP20125415B (en) | 2007-01-05 | 2012-03-12 | Novartis Ag | Imidazole derivatives as kinesin spindle protein inhibitors (eg-5) |
| BRPI0806245B1 (pt) | 2007-01-10 | 2022-01-25 | Msd Italia S.R.L. | Compostos de fórmula i e seus usos |
| WO2009002495A1 (en) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| AU2010232729A1 (en) | 2009-03-31 | 2011-10-20 | Arqule, Inc. | Substituted indolo-pyridinone compounds |
| EP2413932A4 (de) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | Hemmer der akt-aktivität |
| CA2777043C (en) | 2009-10-14 | 2015-12-15 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| EP2584903B1 (de) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Neue heterozyklische verbindungen als erk-hemmer |
| CN103068980B (zh) | 2010-08-02 | 2017-04-05 | 瑟纳治疗公司 | 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制 |
| RU2745848C2 (ru) | 2010-08-17 | 2021-04-01 | Сирна Терапьютикс, Инк. | ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| EP2613782B1 (de) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| WO2012143879A1 (en) | 2011-04-21 | 2012-10-26 | Piramal Healthcare Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| EP2770987B1 (de) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Neue verbindungen als erk-hemmer |
| EP3919620A1 (de) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Zusammensetzungen mit kurzer interferierender nukleinsäure (sina) |
| CA2882950A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| SMT201700595T1 (it) | 2012-11-28 | 2018-03-08 | Merck Sharp & Dohme | Composizioni e metodi per trattare il cancro |
| WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2018023017A1 (en) | 2016-07-29 | 2018-02-01 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| JP7160833B2 (ja) | 2017-04-13 | 2022-10-25 | サイロパ ビー．ブイ． | 抗ｓｉｒｐアルファ抗体 |
| EP3706742B1 (de) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| WO2019094312A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| CA3108388A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033285A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833667B1 (de) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| ES3074517T3 (en) | 2019-12-17 | 2026-07-21 | Merck Sharp & Dohme Llc | 4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease |
| EP4076460B1 (de) | 2019-12-17 | 2026-01-21 | Merck Sharp & Dohme LLC | 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidin]-derivate als prmt5 inhibitoren zur behandlung von krebs |
| EP4076459B1 (de) | 2019-12-17 | 2026-04-29 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| ES3022307T3 (en) | 2019-12-17 | 2025-05-28 | Merck Sharp & Dohme Llc | Prmt5 inhibitors |
| DE212025000115U1 (de) | 2024-07-30 | 2026-06-18 | Sairopa B.V. | Anti-SIRP Alpha-Antikörperformulierungen und ihre Verwendung |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3647790A (en) * | 1969-04-08 | 1972-03-07 | American Home Prod | Ouinoxalinyl-oxazolidines and -oxazines |
| GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
| US6057342A (en) * | 1996-08-16 | 2000-05-02 | Dupont Pharmaceutical Co. | Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof |
| WO1998006694A1 (en) | 1996-08-16 | 1998-02-19 | Du Pont Pharmaceuticals Company | Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof |
| EP1226129B1 (de) * | 1999-10-27 | 2006-05-24 | Cytokinetics, Inc. | Chinazolinone benutzende verfahren und zusammenstellungen |
| US6440686B1 (en) * | 2000-06-15 | 2002-08-27 | Cytokinetics, Inc. | Methods for screening and therapeutic applications of kinesin modulators |
| CA2467916A1 (en) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| IL165624A0 (en) * | 2002-06-14 | 2006-01-15 | Merck & Co Inc | Mitotic kinesin inhibitors |
| US7235580B2 (en) | 2002-10-18 | 2007-06-26 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| US7465746B2 (en) | 2003-08-15 | 2008-12-16 | Merck & Co., Inc. | Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP |
| AR045342A1 (es) | 2003-08-15 | 2005-10-26 | Merck & Co Inc | Inhibidores de quinesina mitotica |
-
2003
- 2003-06-12 AU AU2003276005A patent/AU2003276005B2/en not_active Ceased
- 2003-06-12 JP JP2004513250A patent/JP4463679B2/ja not_active Expired - Fee Related
- 2003-06-12 EP EP03741969A patent/EP1515949B1/de not_active Expired - Lifetime
- 2003-06-12 ES ES03741969T patent/ES2282647T3/es not_active Expired - Lifetime
- 2003-06-12 CA CA002486215A patent/CA2486215A1/en not_active Abandoned
- 2003-06-12 DE DE60312516T patent/DE60312516T2/de not_active Expired - Lifetime
- 2003-06-12 WO PCT/US2003/018694 patent/WO2003106417A1/en not_active Ceased
- 2003-06-12 US US10/517,576 patent/US7301028B2/en not_active Expired - Fee Related
- 2003-06-12 AT AT03741969T patent/ATE356804T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1515949B1 (de) | 2007-03-14 |
| JP2005533063A (ja) | 2005-11-04 |
| US20060063942A1 (en) | 2006-03-23 |
| AU2003276005B2 (en) | 2009-01-15 |
| CA2486215A1 (en) | 2003-12-24 |
| US7301028B2 (en) | 2007-11-27 |
| AU2003276005A1 (en) | 2003-12-31 |
| EP1515949A1 (de) | 2005-03-23 |
| JP4463679B2 (ja) | 2010-05-19 |
| EP1515949A4 (de) | 2005-11-09 |
| ES2282647T3 (es) | 2007-10-16 |
| DE60312516D1 (de) | 2007-04-26 |
| WO2003106417A1 (en) | 2003-12-24 |
| DE60312516T2 (de) | 2007-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60312516D1 (de) | Inhibitoren von mitotischem kinesin | |
| ATE448207T1 (de) | Mitotische kinesin-hemmer | |
| ATE446094T1 (de) | Mitotische kinesin-hemmer | |
| ATE424388T1 (de) | Mitotische kinesinhemmer | |
| ATE447577T1 (de) | Mitotische kinesin-hemmer | |
| DE60222302D1 (de) | Inhibitoren von mitotischem kinesin | |
| ATE421512T1 (de) | Inhibitoren von mitotischem kinesin | |
| WO2004039774A3 (en) | Mitotic kinesin inhibitors | |
| WO2003099211A3 (en) | Mitotic kinesin inhibitors | |
| WO2004058700A3 (en) | Mitotic kinesin inhibitors | |
| WO2004037171A3 (en) | Mitotic kinesin inhibitors | |
| WO2004058148A3 (en) | Mitotic kinesin inhibitors | |
| WO2005017190A3 (en) | Mitotic kinesin inhibitors | |
| WO2005018547A3 (en) | Mitotic kinesin inhibitors | |
| WO2005060654A3 (en) | Mitotic kinesin inhibitors | |
| ECSP066362A (es) | Inhibidores de quinesina mitótica. | |
| WO2005065183A3 (en) | Mitotic kinesin inhibitors | |
| WO2006068933A3 (en) | Mitotic kinesin inhibitors | |
| NO20070589L (no) | Mitotiske kinesin-inhibitorer. | |
| ATE426605T1 (de) | Inhibitoren von mitotischem kinesin | |
| WO2006007496A3 (en) | Mitotic kinesin inhibitors | |
| WO2006007501A3 (en) | Mitotic kinesin inhibitors | |
| WO2004087050A3 (en) | Mitotic kinesin inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |